batimastat

batimastat

A non-cytotoxic inhibitor of matrix metalloproteinase, which inhibits matrix digestion, cell migration and smooth muscle cell migration without interfering with re-endothelialisation. It was first formulated as an anti-cancer drug and later studied for preventing in-stent restenosis, as it selectively targets migrating cells. The BRILLIANT-EU trial concluded that batimastat is no more effective than standard coated stents.

batimastat

Oncology An anticancer angiogenesis inhibitor of matrix metalloproteinase
References in periodicals archive ?
The MMP inhibitors batimastat and marimastat reduce CNV when applied early in the process [93,94], suggesting a potential therapeutic role for MMP9 inhibitors in AMD.
13) showed that HER-2/neu ECD shedding was inhibited by broad-spectrum MMP inhibitors such as EDTA, TAPI-2, and Batimastat and confirmed the data from Christianson et al.
the Batimastat BiodivYsio stent, in pivotal patient trials in Europe, in collaboration with Biocompatibles International plc;
Registry study for the Batimastat BiodivYsio(R) stent in restenosis